Curaleaf (OTCMKTS:CURLF) Trading Down 6.8% – Here’s Why

Shares of Curaleaf Holdings, Inc. (OTCMKTS:CURLF) fell 6.8% on Tuesday . The company traded as low as $2.22 and last traded at $2.2550. 601,954 shares changed hands during trading, a decline of 32% from the average session volume of 884,387 shares. The stock had previously closed at $2.42.

Wall Street Analyst Weigh In

A number of research firms have recently commented on CURLF. Zacks Research raised shares of Curaleaf from a “strong sell” rating to a “hold” rating in a research report on Thursday, January 1st. Alliance Global Partners reissued a “buy” rating on shares of Curaleaf in a research report on Monday, December 22nd. Two investment analysts have rated the stock with a Strong Buy rating, one has assigned a Buy rating and one has assigned a Hold rating to the stock. According to MarketBeat.com, the company has an average rating of “Buy”.

Curaleaf Trading Down 6.6%

The business’s 50-day moving average price is $2.31 and its 200 day moving average price is $2.59. The company has a debt-to-equity ratio of 1.14, a current ratio of 1.52 and a quick ratio of 0.76. The firm has a market capitalization of $1.54 billion, a price-to-earnings ratio of -7.53 and a beta of 0.77.

Curaleaf (OTCMKTS:CURLF) last posted its earnings results on Thursday, February 26th. The company reported ($0.05) EPS for the quarter, topping analysts’ consensus estimates of ($0.08) by $0.03. Curaleaf had a negative net margin of 18.08% and a negative return on equity of 23.17%. The business had revenue of $333.07 million for the quarter, compared to analysts’ expectations of $328.70 million. On average, equities analysts forecast that Curaleaf Holdings, Inc. will post -0.25 earnings per share for the current fiscal year.

Curaleaf Company Profile

Curaleaf Holdings, Inc is a leading American cannabis company engaged in the cultivation, processing and distribution of both medical and adult-use cannabis products. Headquartered in Wakefield, Massachusetts, Curaleaf operates cultivation facilities, processing centers and retail dispensaries across multiple U.S. jurisdictions. The company’s vertically integrated model allows it to manage the entirety of its supply chain, from seed to sale, ensuring consistent quality and compliance with stringent regulatory requirements.

Curaleaf’s product portfolio spans a wide range of formats, including premium flower, vaporizer cartridges, edibles, tinctures, topicals and concentrates.